PTC Therapeutics | PTCT - Operating Profit


PTC Therapeutics reported $148.98M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Novartis USD 5.14B 392M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026